Displaying 481 - 500 of 1537
FTC to Conduct Workshop on November 8, Examining Competition Issues Related to Prescription Drug Markets
FTC Requires Abbott Laboratories to Divest Two Types of Point-Of-Care Medical Testing Devices as Condition of Acquiring Alere Inc.
FTC Requires Divestiture of 5 Medical Device Product Lines as Condition of Integra Acquiring Johnson & Johnson’s Codman Neuro Division
Grifols, S.A., and Talecris Biotherapeutics Holdings Corp., In the Matter of
The FTC required Grifols, S.A., a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. It resolves FTC charges that Grifols’ proposed acquisition of Talecris would be anticompetitive and would violate federal antitrust laws. As part of the settlement, Grifols will sell the Talecris fractionation facility in Melville, New York, and Grifols’ plasma collection centers in Mobile, Alabama, and Winston-Salem, North Carolina, to Kedrion S.p.A. Kedrion is a manufacturer of plasma-derived products in Europe and other markets, and will be a new entrant in the U.S. plasma-derived products industry. Grifols also will manufacture three plasma-derived products for Kedrion for several years under a manufacturing agreement. The FTC approved a final order on July 22, 2011.
FTC Final Order with Baxter International and Claris Lifesciences Preserves U.S. Competition for the Injectable Drugs Intravenous Fluconazole and Intravenous Milrinone
Price Effects of a Merger: Evidence from a Physicians’ Market
FTC to Join CDC Twitter Chat on Healthy Contact Lens Wear and Care
Aqua Health Labs, Inc. (PhytOriginal dietary supplements)
Doctors Hospital at Renaissance/Mission Regional Medical Center
FTC Staff Provides Additional Comment and Testimony in Tennessee Opposing Mountain States’ and Wellmont’s Certificate of Public Advantage Application
Tennessee Department of Health, Certificate of Public Advantage Hearing Testimony
Wellmont Health System/Mountain States Health Alliance
FTC Approves Sublicense for Synacthen Depot Submitted by Mallinckrodt ARD Inc.
Mallinckrodt Ard Inc. (Questcor Pharmaceuticals)
Mallinckrodt ARD Inc., formerly known as Questcor Pharmaceuticals, Inc., and its parent company, Mallinckrodt plc, agreed to pay $100 million to settle charges that they violated the antitrust laws when Questcor acquired the rights to a drug that threatened its monopoly in the U.S. market for adrenocorticotropic hormone (ACTH) drugs. Acthar is a specialty drug used as a treatment for infantile spasms, a rare seizure disorder afflicting infants, as well a drug of last resort used to treat other serious medical conditions. The complaint alleges that, while benefitting from an existing monopoly over the only U.S. ACTH drug, Acthar, Questcor illegally acquired the U.S. rights to develop a competing drug, Synacthen Depot. The acquisition stifled competition by preventing any other company from using the Synacthen assets to develop a synthetic ACTH drug, preserving Questcor’s monopoly and allowing it to maintain extremely high prices for Acthar. In addition to the $100 million monetary payment, the proposed stipulated court order, which must be approved by the federal court, requires that Questcor grant a license to develop Synacthen Depot to treat infantile spasms and nephrotic syndrome to a licensee approved by the Commission.
FTC and State Attorney General Challenge Physician Group Acquisition in North Dakota
CellMark Biopharma, LLC & Lexium International LLC
Displaying 481 - 500 of 1537